(function(){var loadHandler=window['sl_{5C30CC7C-43B9-4E83-9F5F-A086153E4BBA}'];loadHandler&&loadHandler(13, '<div id="spr0_52d5d36"><div id="spr1_52d5d36" class="kern"><img id="img3_52d5d36" src="data/img3.png" width="960px" height="540px" alt="" style="left:0px;top:0px;"/><div id="spr3_52d5d36" style="left:222.976px;top:165.764px;"><img id="img0_52d5d36" src="data/img0.png" width="737" height="374" alt="" style="left:0.012px;top:0.118px;"/></div><div id="spr4_52d5d36"><img id="img1_52d5d36" src="data/img1.png" width="960" height="540" alt="" style="left:-0.084px;"/></div><div id="svg0_52d5d36" style="left:0px;top:0px;"><svg width="76" height="540" viewBox="0 0 76 540"><path fill="#39302a" d="M0,0 h75.919 v540 h-75.919 Z"/></svg></div><div id="svg1_52d5d36" style="left:75.751px;"><svg width="4" height="540" viewBox="0 0 4 540"><path fill="#9c6a6a" d="M0,0 h3.6 v540 h-3.6 Z"/></svg></div><div id="svg2_52d5d36" style="left:79.093px;"><svg width="817" height="540" viewBox="0 0 817 540"><path fill="#39302a" fill-opacity="0.92" d="M0,0 h816.718 v540 h-816.718 Z"/></svg></div><div id="svg3_52d5d36" style="left:895.853px;"><svg width="3" height="540" viewBox="0 0 3 540"><path fill="#9c6a6a" d="M0,0 h2.16 v540 h-2.16 Z"/></svg></div><div id="spr5_52d5d36" style="left:172.83px;top:50.49px;"><div style="width:0px;"><span id="txt0_52d5d36" class="relpos" style="left:9.575px;top:4.499px;"></span></div></div></div><div id="spr2_52d5d36" class="kern"><div id="svg4_52d5d36" style="left:702.223px;top:62.876px;"><svg width="131" height="47" viewBox="-0.375 -0.375 131 47"><path fill="none" stroke="#e5dedb" stroke-width="0.8" stroke-linecap="butt" stroke-linejoin="round" d="M0.375,0.375 h129.321 v45.347 h-129.321 Z"/></svg></div><div id="spr6_52d5d36" style="left:702.598px;top:63.251px;"><div style="width:0px;"><span id="txt1_52d5d36" class="relpos" style="left:9.225px;top:1.597px;">Results</span></div></div><div id="spr7_52d5d36" style="left:93.892px;top:150.811px;"><div style="width:0px;"><span id="txt2_52d5d36" class="nokern relpos" style="left:7.71px;top:49.198px;"></span><span id="txt3_52d5d36" class="relpos" style="left:26.115px;top:47.131px;">PTBD were use 35/98 patients (35.7%) in group I and 12/34 ( 35.3%) in group II.</span></div><div style="width:0px;"><span id="txt4_52d5d36" class="nokern relpos" style="left:7.71px;top:88.998px;"></span><span id="txt5_52d5d36" class="relpos" style="left:26.115px;top:86.931px;">ERCP were performed in all of the patients in group I and 30/34 patients in group II .</span></div><div style="width:0px;"><span id="txt6_52d5d36" class="nokern relpos" style="left:7.71px;top:128.798px;"></span><span id="txt7_52d5d36" class="relpos" style="left:26.115px;top:126.731px;">Four patients in group I were treated by EUS-BD and 31 patients in group II were</span></div><div style="width:0px;"><span id="txt8_52d5d36" class="relpos" style="left:34.35px;top:155.531px;">performed EUS-BD.</span></div></div><div id="spr8_52d5d36"><img id="img2_52d5d36" src="data/img2.png" width="446" height="70" alt="" style="left:0.219px;top:0.043px;"/></div></div></div>');})();